SCHEMBL7103316

SCHEMBL7103316

Cc1ccc(Cc2cn(S(=O)(=O)N(C)C)cn2)cc1NS(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
ATM Q13315 2/20 0.38
NPC1 O15118 2/20 0.37
POLB P06746 1/20 0.36
BACE1 P56817 4/20 0.36
ADRA2A P08913 2/20 0.35
ADRA2B P18089 2/20 0.35
ADRA2C P18825 2/20 0.35
ADRA1A P35348 2/20 0.35
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 3/20 0.33
RAB9A P51151 1/20 0.33
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
CECR2 Q9BXF3 1/20 0.33
BRD9 Q9H8M2 1/20 0.33
NR3C1 P04150 1/20 0.33
GAA P10253 2/20 0.32
NPY1R P25929 1/20 0.32
CCNT1 O60563 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7098113 0.90 SMN1; SMN2 (0.39) MAPTATMNPC1ALDH1A1KDM4E
SCHEMBL7102010 0.81 PARP1 (0.36) KDM4EGAAHTTFGFR1FGFR2
SCHEMBL7100325 0.78 NR3C1 (0.37) NR3C1
SCHEMBL3747951 0.75 BACE1 (0.43) BACE1LMNASMN1; SMN2FGFR1FGFR2
SCHEMBL22075719 0.74 MEN1 (0.41) MAPTATMALDH1A1KDM4ELMNA
SCHEMBL7252794 0.73 CA1 (0.39) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL7099288 0.72 MAPT (0.43) MAPTATMNPC1POLBBACE1
SCHEMBL7103434 0.68 FGFR1 (0.31) NR3C1SMN1; SMN2FGFR1FGFR2FGFR4
SCHEMBL12299574 0.68 MAPT (0.67) MAPTATMNPC1POLBBACE1
SCHEMBL5504526 0.68 BACE1 (0.43) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ABBOTT LABORATORIES 2003-04-17 US disclosed
EP-1259491-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS Abbott Laboratories (US) 2002-11-27 EP disclosed
WO-2001060802-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS ABBOTT LABORATORIES (US) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ADRA1D, ADRB1, ADRA1A MAPT 4075/4885ATM 4133/4885NPC1 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.